CN111876400B - Normal temperature lyase Sly and polynucleotide for coding same - Google Patents
Normal temperature lyase Sly and polynucleotide for coding same Download PDFInfo
- Publication number
- CN111876400B CN111876400B CN202010780549.2A CN202010780549A CN111876400B CN 111876400 B CN111876400 B CN 111876400B CN 202010780549 A CN202010780549 A CN 202010780549A CN 111876400 B CN111876400 B CN 111876400B
- Authority
- CN
- China
- Prior art keywords
- lyase
- sly
- enzyme
- room temperature
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000856 Lyases Proteins 0.000 title claims abstract description 71
- 102000004317 Lyases Human genes 0.000 title claims abstract description 66
- 108091033319 polynucleotide Proteins 0.000 title claims abstract description 6
- 239000002157 polynucleotide Substances 0.000 title claims abstract description 6
- 102000040430 polynucleotide Human genes 0.000 title claims abstract description 6
- 239000002773 nucleotide Substances 0.000 claims abstract description 8
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- 241000894006 Bacteria Species 0.000 abstract description 17
- 230000003197 catalytic effect Effects 0.000 abstract description 9
- 241000192125 Firmicutes Species 0.000 abstract 1
- 238000010353 genetic engineering Methods 0.000 abstract 1
- 102000004190 Enzymes Human genes 0.000 description 35
- 108090000790 Enzymes Proteins 0.000 description 35
- 229940088598 enzyme Drugs 0.000 description 35
- 239000000243 solution Substances 0.000 description 31
- 230000000694 effects Effects 0.000 description 30
- 239000013612 plasmid Substances 0.000 description 26
- 238000006243 chemical reaction Methods 0.000 description 24
- 108090000623 proteins and genes Proteins 0.000 description 24
- 230000001580 bacterial effect Effects 0.000 description 19
- 102000004169 proteins and genes Human genes 0.000 description 17
- 235000018102 proteins Nutrition 0.000 description 15
- 241000588724 Escherichia coli Species 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000000758 substrate Substances 0.000 description 13
- 241000191967 Staphylococcus aureus Species 0.000 description 12
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 11
- 239000008101 lactose Substances 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 10
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000001976 enzyme digestion Methods 0.000 description 10
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 10
- 230000009471 action Effects 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 238000001962 electrophoresis Methods 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 239000006228 supernatant Substances 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 230000003321 amplification Effects 0.000 description 6
- 239000003242 anti bacterial agent Substances 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 210000002421 cell wall Anatomy 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 229930027917 kanamycin Natural products 0.000 description 6
- 229960000318 kanamycin Drugs 0.000 description 6
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 6
- 229930182823 kanamycin A Natural products 0.000 description 6
- 229910021645 metal ion Inorganic materials 0.000 description 6
- 238000003199 nucleic acid amplification method Methods 0.000 description 6
- 239000002244 precipitate Substances 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- MSFSPUZXLOGKHJ-UHFFFAOYSA-N Muraminsaeure Natural products OC(=O)C(C)OC1C(N)C(O)OC(CO)C1O MSFSPUZXLOGKHJ-UHFFFAOYSA-N 0.000 description 5
- 108010013639 Peptidoglycan Proteins 0.000 description 5
- 241000607142 Salmonella Species 0.000 description 5
- 241000607768 Shigella Species 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 239000010200 folin Substances 0.000 description 5
- 238000011081 inoculation Methods 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 101100221834 Caenorhabditis elegans cpl-1 gene Proteins 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 4
- 239000005018 casein Substances 0.000 description 4
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 4
- 235000021240 caseins Nutrition 0.000 description 4
- 238000003235 crystal violet staining Methods 0.000 description 4
- 230000002779 inactivation Effects 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 230000009182 swimming Effects 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241001515965 unidentified phage Species 0.000 description 3
- UTKUTMJSWKKHEM-WDSKDSINSA-N Glu-Ala-Gly Chemical compound OC(=O)CNC(=O)[C@H](C)NC(=O)[C@@H](N)CCC(O)=O UTKUTMJSWKKHEM-WDSKDSINSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 238000007664 blowing Methods 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 108010057821 leucylproline Proteins 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 239000012474 protein marker Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 239000012192 staining solution Substances 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 2
- GWFSQQNGMPGBEF-GHCJXIJMSA-N Ala-Asp-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](C)N GWFSQQNGMPGBEF-GHCJXIJMSA-N 0.000 description 1
- NMXKFWOEASXOGB-QSFUFRPTSA-N Ala-Ile-His Chemical compound C[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@H](C(O)=O)CC1=CN=CN1 NMXKFWOEASXOGB-QSFUFRPTSA-N 0.000 description 1
- BLTRAARCJYVJKV-QEJZJMRPSA-N Ala-Lys-Phe Chemical compound C[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](Cc1ccccc1)C(O)=O BLTRAARCJYVJKV-QEJZJMRPSA-N 0.000 description 1
- HOVPGJUNRLMIOZ-CIUDSAMLSA-N Ala-Ser-Leu Chemical compound CC(C)C[C@@H](C(O)=O)NC(=O)[C@H](CO)NC(=O)[C@H](C)N HOVPGJUNRLMIOZ-CIUDSAMLSA-N 0.000 description 1
- 108090000531 Amidohydrolases Proteins 0.000 description 1
- 102000004092 Amidohydrolases Human genes 0.000 description 1
- NYZGVTGOMPHSJW-CIUDSAMLSA-N Arg-Glu-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CS)C(=O)O)N)CN=C(N)N NYZGVTGOMPHSJW-CIUDSAMLSA-N 0.000 description 1
- NMRHDSAOIURTNT-RWMBFGLXSA-N Arg-Leu-Pro Chemical compound CC(C)C[C@@H](C(=O)N1CCC[C@@H]1C(=O)O)NC(=O)[C@H](CCCN=C(N)N)N NMRHDSAOIURTNT-RWMBFGLXSA-N 0.000 description 1
- CLICCYPMVFGUOF-IHRRRGAJSA-N Arg-Lys-Leu Chemical compound [H]N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O CLICCYPMVFGUOF-IHRRRGAJSA-N 0.000 description 1
- VXLBDJWTONZHJN-YUMQZZPRSA-N Asn-His-Gly Chemical compound C1=C(NC=N1)C[C@@H](C(=O)NCC(=O)O)NC(=O)[C@H](CC(=O)N)N VXLBDJWTONZHJN-YUMQZZPRSA-N 0.000 description 1
- RPUYTJJZXQBWDT-SRVKXCTJSA-N Asp-Phe-Ser Chemical compound C1=CC=C(C=C1)C[C@@H](C(=O)N[C@@H](CO)C(=O)O)NC(=O)[C@H](CC(=O)O)N RPUYTJJZXQBWDT-SRVKXCTJSA-N 0.000 description 1
- UXRVDHVARNBOIO-QSFUFRPTSA-N Asp-Val-Ile Chemical compound CC[C@H](C)[C@@H](C(=O)O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)N UXRVDHVARNBOIO-QSFUFRPTSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000193755 Bacillus cereus Species 0.000 description 1
- 208000031729 Bacteremia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 241000620209 Escherichia coli DH5[alpha] Species 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- CYTSBCIIEHUPDU-ACZMJKKPSA-N Gln-Asp-Ala Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(O)=O CYTSBCIIEHUPDU-ACZMJKKPSA-N 0.000 description 1
- PSERKXGRRADTKA-MNXVOIDGSA-N Gln-Leu-Ile Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O PSERKXGRRADTKA-MNXVOIDGSA-N 0.000 description 1
- VEYGCDYMOXHJLS-GVXVVHGQSA-N Gln-Val-Leu Chemical compound [H]N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O VEYGCDYMOXHJLS-GVXVVHGQSA-N 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- UGVQELHRNUDMAA-BYPYZUCNSA-N Gly-Ala-Gly Chemical compound [NH3+]CC(=O)N[C@@H](C)C(=O)NCC([O-])=O UGVQELHRNUDMAA-BYPYZUCNSA-N 0.000 description 1
- JRDYDYXZKFNNRQ-XPUUQOCRSA-N Gly-Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)CN JRDYDYXZKFNNRQ-XPUUQOCRSA-N 0.000 description 1
- RQZGFWKQLPJOEQ-YUMQZZPRSA-N Gly-Arg-Gln Chemical compound C(C[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)O)NC(=O)CN)CN=C(N)N RQZGFWKQLPJOEQ-YUMQZZPRSA-N 0.000 description 1
- XUORRGAFUQIMLC-STQMWFEESA-N Gly-Arg-Tyr Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CN)O XUORRGAFUQIMLC-STQMWFEESA-N 0.000 description 1
- ITZOBNKQDZEOCE-NHCYSSNCSA-N Gly-Ile-Lys Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CCCCN)C(=O)O)NC(=O)CN ITZOBNKQDZEOCE-NHCYSSNCSA-N 0.000 description 1
- BQFGKVYHKCNEMF-DCAQKATOSA-N His-Glu-Gln Chemical compound NC(=O)CC[C@@H](C(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CC1=CN=CN1 BQFGKVYHKCNEMF-DCAQKATOSA-N 0.000 description 1
- VSZALHITQINTGC-GHCJXIJMSA-N Ile-Ala-Asp Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)O)N VSZALHITQINTGC-GHCJXIJMSA-N 0.000 description 1
- WUEIUSDAECDLQO-NAKRPEOUSA-N Ile-Ala-Met Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)O)N WUEIUSDAECDLQO-NAKRPEOUSA-N 0.000 description 1
- PELCGFMHLZXWBQ-BJDJZHNGSA-N Ile-Ser-Leu Chemical compound CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)O)N PELCGFMHLZXWBQ-BJDJZHNGSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KNKHAVVBVXKOGX-JXUBOQSCSA-N Lys-Ala-Thr Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O KNKHAVVBVXKOGX-JXUBOQSCSA-N 0.000 description 1
- SVJRVFPSHPGWFF-DCAQKATOSA-N Lys-Cys-Arg Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O SVJRVFPSHPGWFF-DCAQKATOSA-N 0.000 description 1
- MUXNCRWTWBMNHX-SRVKXCTJSA-N Lys-Leu-Asp Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O MUXNCRWTWBMNHX-SRVKXCTJSA-N 0.000 description 1
- WVJNGSFKBKOKRV-AJNGGQMLSA-N Lys-Leu-Ile Chemical compound [H]N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(O)=O WVJNGSFKBKOKRV-AJNGGQMLSA-N 0.000 description 1
- CUHGAUZONORRIC-HJGDQZAQSA-N Lys-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](CCCCN)N)O CUHGAUZONORRIC-HJGDQZAQSA-N 0.000 description 1
- QGQGAIBGTUJRBR-NAKRPEOUSA-N Met-Ala-Ile Chemical compound CC[C@H](C)[C@@H](C(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CCSC QGQGAIBGTUJRBR-NAKRPEOUSA-N 0.000 description 1
- AFFKUNVPPLQUGA-DCAQKATOSA-N Met-Leu-Ala Chemical compound [H]N[C@@H](CCSC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(O)=O AFFKUNVPPLQUGA-DCAQKATOSA-N 0.000 description 1
- UNPGTBHYKJOCCZ-DCAQKATOSA-N Met-Lys-Ala Chemical compound CSCC[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O UNPGTBHYKJOCCZ-DCAQKATOSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010047562 NGR peptide Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- YKUGPVXSDOOANW-KKUMJFAQSA-N Phe-Leu-Asp Chemical compound [H]N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(O)=O YKUGPVXSDOOANW-KKUMJFAQSA-N 0.000 description 1
- RMODQFBNDDENCP-IHRRRGAJSA-N Pro-Lys-Leu Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O RMODQFBNDDENCP-IHRRRGAJSA-N 0.000 description 1
- RMJZWERKFFNNNS-XGEHTFHBSA-N Pro-Thr-Ser Chemical compound [H]N1CCC[C@H]1C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(O)=O RMJZWERKFFNNNS-XGEHTFHBSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108091036333 Rapid DNA Proteins 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- HZWAHWQZPSXNCB-BPUTZDHNSA-N Ser-Arg-Trp Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(O)=O HZWAHWQZPSXNCB-BPUTZDHNSA-N 0.000 description 1
- SFZKGGOGCNQPJY-CIUDSAMLSA-N Ser-Asp-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)N SFZKGGOGCNQPJY-CIUDSAMLSA-N 0.000 description 1
- YRBGKVIWMNEVCZ-WDSKDSINSA-N Ser-Glu-Gly Chemical compound OC[C@H](N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(O)=O YRBGKVIWMNEVCZ-WDSKDSINSA-N 0.000 description 1
- VZQRNAYURWAEFE-KKUMJFAQSA-N Ser-Leu-Phe Chemical compound OC[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 VZQRNAYURWAEFE-KKUMJFAQSA-N 0.000 description 1
- HDBOEVPDIDDEPC-CIUDSAMLSA-N Ser-Lys-Asn Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(O)=O HDBOEVPDIDDEPC-CIUDSAMLSA-N 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- MFEBUIFJVPNZLO-OLHMAJIHSA-N Thr-Asp-Asn Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O MFEBUIFJVPNZLO-OLHMAJIHSA-N 0.000 description 1
- DCLBXIWHLVEPMQ-JRQIVUDYSA-N Thr-Asp-Tyr Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 DCLBXIWHLVEPMQ-JRQIVUDYSA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- GAYLGYUVTDMLKC-UWJYBYFXSA-N Tyr-Asp-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 GAYLGYUVTDMLKC-UWJYBYFXSA-N 0.000 description 1
- JWGXUKHIKXZWNG-RYUDHWBXSA-N Tyr-Gly-Gln Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)NCC(=O)N[C@@H](CCC(=O)N)C(=O)O)N)O JWGXUKHIKXZWNG-RYUDHWBXSA-N 0.000 description 1
- ZOBLBMGJKVJVEV-BZSNNMDCSA-N Tyr-Lys-Lys Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)O)N)O ZOBLBMGJKVJVEV-BZSNNMDCSA-N 0.000 description 1
- PIFJAFRUVWZRKR-QMMMGPOBSA-N Val-Gly-Gly Chemical compound CC(C)[C@H]([NH3+])C(=O)NCC(=O)NCC([O-])=O PIFJAFRUVWZRKR-QMMMGPOBSA-N 0.000 description 1
- RLVTVHSDKHBFQP-ULQDDVLXSA-N Val-Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)CC1=CC=C(O)C=C1 RLVTVHSDKHBFQP-ULQDDVLXSA-N 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 108010011559 alanylphenylalanine Proteins 0.000 description 1
- VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 1
- 108010092854 aspartyllysine Proteins 0.000 description 1
- 229940065181 bacillus anthracis Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000008952 bacterial invasion Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- FSXRLASFHBWESK-UHFFFAOYSA-N dipeptide phenylalanyl-tyrosine Natural products C=1C=C(O)C=CC=1CC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FSXRLASFHBWESK-UHFFFAOYSA-N 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 229940066758 endopeptidases Drugs 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000006862 enzymatic digestion Effects 0.000 description 1
- 239000003248 enzyme activator Substances 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- XBGGUPMXALFZOT-UHFFFAOYSA-N glycyl-L-tyrosine hemihydrate Natural products NCC(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 XBGGUPMXALFZOT-UHFFFAOYSA-N 0.000 description 1
- 108010027668 glycyl-alanyl-valine Proteins 0.000 description 1
- 108010089804 glycyl-threonine Proteins 0.000 description 1
- 108010045126 glycyl-tyrosyl-glycine Proteins 0.000 description 1
- 108010050848 glycylleucine Proteins 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010085325 histidylproline Proteins 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000036457 multidrug resistance Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 108010026333 seryl-proline Proteins 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 108010033670 threonyl-aspartyl-tyrosine Proteins 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
Description
技术领域technical field
本发明属于生物技术领域,具体涉及一种常温裂解酶Sly以及编码此酶的核苷酸序列。The invention belongs to the field of biotechnology, in particular to a room temperature lyase Sly and a nucleotide sequence encoding the enzyme.
背景技术Background technique
近年来,由于抗生素的不合理使用,引起了细菌多重耐药性、药物残留、食品安全、环境菌群不平衡等问题,严重威胁人类及动物的健康。人们迫切需要研究新型的抗菌试剂,而细菌的天敌噬菌体给人们抵抗细菌入侵提供了新的思路,越来越多的人开始尝试用噬菌体裂解酶治疗细菌感染。In recent years, due to the irrational use of antibiotics, problems such as multi-drug resistance of bacteria, drug residues, food safety, and environmental flora imbalance have been caused, which seriously threaten the health of humans and animals. There is an urgent need to study new antibacterial reagents, and phages, the natural enemies of bacteria, provide new ideas for people to resist bacterial invasion. More and more people are trying to use phage lyases to treat bacterial infections.
噬菌体裂解酶(以下简称裂解酶)是噬菌体浸染宿主末期表达的一类肽聚糖水解酶,可以快速的降解宿主菌细胞壁上的肽聚糖,使感染的细菌裂解并且释放出子代噬菌体颗粒。根据作用于肽聚糖共价键位点的不同,可将噬菌体裂解酶分为葡糖苷酶、酰胺酶、内肽酶和转糖基酶。此外,裂解酶具有典型的模块化结构,包括N端催化域结构(CatalyticDomain,CD)和C端细胞壁结合域结构(Cell-wall binding domain,CBD)。催化域结构具有催化活性,能够特异地切断细菌细胞壁上肽聚糖的化学键;结合域结构可以与宿主细菌细胞壁上的特异性底物结合,介导催化域结构与作用靶点的有效结合与切割。此外,据Rehman推算地球上大概有1032个噬菌体存在,这个数据大概是细菌数量的10倍。可以说,凡是有细菌分布的地方,就会有噬菌体存在。因此,裂解酶作为来源广泛的抗生素替代物吸引了众多研究人员的目光。Phage lyase (hereinafter referred to as lyase) is a type of peptidoglycan hydrolase expressed at the end of phage infection of the host, which can rapidly degrade the peptidoglycan on the cell wall of the host bacteria, lyse the infected bacteria and release progeny phage particles. Phage lyases can be classified into glucosidases, amidases, endopeptidases, and transglycosylases according to their role in the covalent bond sites of peptidoglycan. In addition, lyases have a typical modular structure, including N-terminal catalytic domain (CatalyticDomain, CD) and C-terminal cell-wall binding domain (Cell-wall binding domain, CBD). The catalytic domain structure has catalytic activity and can specifically cut the chemical bonds of peptidoglycan on the bacterial cell wall; the binding domain structure can bind to specific substrates on the host bacterial cell wall, mediating the effective binding and cleavage of the catalytic domain structure and the target. . In addition, according to Rehman's calculations, there are about 10 32 bacteriophages on the earth, which is about 10 times the number of bacteria. It can be said that wherever there is a distribution of bacteria, there will be bacteriophages. Therefore, lyases have attracted the attention of many researchers as a wide-ranging alternative to antibiotics.
相关研究表明,裂解酶有许多优势。首先,裂解酶的特异性相较于抗生素更好,相较于噬菌体,裂解谱又扩大了。研究发现,对青霉素耐药的肺炎链球菌菌株可以被裂解酶杀死,同时对人体的正常菌群没有影响,而抗生素在杀死病原菌的同时,也损伤了部分正常菌群。其次,裂解酶的作用高效迅速,裂解酶在体外与细菌接触的瞬间迅速破裂细菌细胞,可使细菌浊度迅速下降。Schuch等将2个单位(2μg)的炭疽芽胞杆菌γ噬菌体裂解酶PlyG加入1.0×104耐链霉素的蜡样芽孢杆菌RSVF1中,10s内就能使细菌裂解。最后,无论是裂解酶之间或裂解酶与抗生素之间,都具有协同效应。Jado等发现低浓度Dp-1和低浓度Cpl-1共同使用时,可以使小鼠全部存活,而Dp-1或Cpl-1单独使用时,因严重的菌血症小鼠全部死亡。Djurkovic等发现将裂解酶Cpl-1与庆大霉素联用,可降低青霉素对肺炎链球菌的最小抑菌浓度。当Cpl-1与青霉素联用时,亦可以协同杀死对青霉素耐药的菌株。Related studies have shown that lyases have many advantages. First, the specificity of lyases is better than that of antibiotics, and the spectrum of lysis is expanded compared to phages. The study found that penicillin-resistant Streptococcus pneumoniae strains can be killed by lyase without affecting the normal flora of the human body, while antibiotics kill pathogenic bacteria and damage part of the normal flora. Secondly, the action of lyase is efficient and rapid, and the lyase rapidly ruptures bacterial cells at the moment of contact with bacteria in vitro, which can rapidly decrease bacterial turbidity. Schuch et al. added 2 units (2 μg) of Bacillus anthracis γ phage lyase PlyG to 1.0×10 4 streptomycin-resistant Bacillus cereus RSVF1, and the bacteria could be lysed within 10s. Finally, there is a synergistic effect either between lyases or between lyases and antibiotics. Jado et al. found that when low concentrations of Dp-1 and low concentrations of Cpl-1 were used together, all mice could survive, while when Dp-1 or Cpl-1 was used alone, all mice died due to severe bacteremia. Djurkovic et al found that the combination of lyase Cpl-1 and gentamicin can reduce the minimum inhibitory concentration of penicillin against Streptococcus pneumoniae. When Cpl-1 is used in combination with penicillin, it can also synergistically kill penicillin-resistant strains.
广泛的研究表明,裂解酶具有高效性、高稳定性、潜在广泛杀菌性和安全性,能特异性的杀灭细菌而且不容易使细菌产生耐药性;裂解酶在抗菌方面具有较大的开发价值,有望成为抗生素的替代品,具有广阔的应用前景。Extensive studies have shown that lyase has high efficiency, high stability, potential broad bactericidal and safety, can kill bacteria specifically and is not easy to make bacteria resistant to bacteria; lyase has great development in antibacterial. It is expected to become a substitute for antibiotics and has broad application prospects.
发明内容SUMMARY OF THE INVENTION
本发明旨在提供一种常温裂解酶Sly,该裂解酶能够抑制部分革兰氏阳性和阴性细菌的生长,其在20℃~50℃范围内具有催化活性,其来源于噬菌体SP26。该常温裂解酶Sly的氨基酸序列如SEQ ID NO:1所示,或具有与SEQ ID NO:1所示的氨基酸序列至少90%的相同性的多肽、类似物或衍生物。The present invention aims to provide a room temperature lyase Sly, which can inhibit the growth of some Gram-positive and negative bacteria, has catalytic activity in the range of 20°C to 50°C, and is derived from bacteriophage SP26. The amino acid sequence of the room temperature lyase Sly is shown in SEQ ID NO: 1, or a polypeptide, analog or derivative having at least 90% identity with the amino acid sequence shown in SEQ ID NO: 1.
本发明的另一个目的是提供编码常温裂解酶Sly的多核苷酸,其核苷酸序列如SEQID NO:2所示,或其互补序列,或具有与SEQ ID NO:2所示的核苷酸序列至少80%相同性的多核苷酸及其互补序列。Another object of the present invention is to provide a polynucleotide encoding a room temperature lyase Sly, the nucleotide sequence of which is shown in SEQ ID NO: 2, or its complementary sequence, or a nucleotide with the nucleotide shown in SEQ ID NO: 2 Polynucleotides with at least 80% sequence identity and their complements.
本发明的有益效果:Beneficial effects of the present invention:
本发明所述裂解酶在20℃~50℃范围内具有催化活性,在37℃催化活性最高,pH值在6~10之间酶活较高,Mg2+、Na+、K+这三种离子对酶有激活作用,本发明常温裂解酶能高效裂解细菌,使其有望取代传统的抗生素治疗,也可作为抑菌剂用于环境的杀菌;其核苷酸序列可用于构建生产此裂解酶的基因工程菌株。The lyase of the present invention has catalytic activity in the range of 20°C to 50°C, the highest catalytic activity at 37°C, and higher enzymatic activity when the pH value is between 6 and 10. The ion has an activating effect on the enzyme, and the room temperature lyase of the present invention can efficiently lyse bacteria, so that it is expected to replace the traditional antibiotic treatment, and can also be used as a bacteriostatic agent for the sterilization of the environment; its nucleotide sequence can be used to construct and produce the lyase genetically engineered strains.
附图说明Description of drawings
图1是本发明常温裂解酶Sly基因PCR产物电泳示意图,其中泳道1代表Marker;泳道2为阴性对照;泳道3为Sly基因PCR产物;Fig. 1 is the electrophoresis schematic diagram of the PCR product of the Sly gene of the lyase at room temperature of the present invention, wherein the
图2是本发明中重组质粒pET28a-Sly双酶切图谱示意图,其中泳道1代表Marker,泳道2为未经双酶切的重组质粒pET28a-Sly条带;泳道3为双酶切后重组质粒pET28a-Sly产生的两个条带;Fig. 2 is a schematic diagram of the double-enzyme digestion map of the recombinant plasmid pET28a-Sly in the present invention, wherein
图3是本发明中常温裂解酶Sly的蛋白表达检测示意图,其中泳道1为GenStarM221-01蛋白Marker;泳道2为pET28a-Sly/Rosetta未诱导全蛋白;泳道3为pET28a-Sly/Rosetta于37℃、150rpm、乳糖(1g/L)诱导6h全蛋白;泳道4为pET28a-Sly/Rosetta于37℃、150rpm、乳糖(1g/L)诱导6h上清;泳道5为pET28a-Sly/Rosetta于37℃、150rpm、乳糖(1g/L)诱导8h全蛋白;泳道6为pET28a-Sly/Rosetta于37℃、150rpm、乳糖(1g/L)诱导8h上清;泳道7为pET28a-Sly/Rosetta于37℃、150 rpm、乳糖(1 g/L)诱导10h全蛋白;泳道8为pET28a-Sly/Rosetta于37℃、150rpm、乳糖(1g/L)诱导10h上清;泳道9为pET28a-Sly/Rosetta于37℃、150rpm、乳糖(1g/L)诱导12h全蛋白;泳道10为pET28a-Sly/Rosetta于37℃、150rpm、乳糖(1g/L)诱导12h上清;Figure 3 is a schematic diagram of the protein expression detection of the room temperature lyase Sly in the present invention, wherein the
图4是本发明常温裂解酶Sly蛋白的纯化结果检测示意图,其中1为GenStar M221-01蛋白Marker,2为上柱后500 mM的咪唑缓冲液过柱后第二管;Fig. 4 is a schematic diagram of the detection of the purification result of the room temperature lyase Sly protein of the present invention, wherein 1 is the GenStar M221-01 protein Marker, and 2 is the second tube after the imidazole buffer of 500 mM after the column is passed through the column;
图5是本发明中不同温度对常温裂解酶Sly活性的影响结果示意图;Fig. 5 is a schematic diagram of the effect of different temperatures on the activity of room temperature lyase Sly in the present invention;
图6是本发明中不同pH值对常温裂解酶Sly活性的影响结果示意图;6 is a schematic diagram of the effect of different pH values on the activity of room temperature lyase Sly in the present invention;
图7是本发明中不同金属离子对常温裂解酶Sly活性的影响结果示意图;7 is a schematic diagram of the effect of different metal ions on the activity of room temperature lyase Sly in the present invention;
图8是本发明常温裂解酶Sly作用于大肠杆菌CMCC(B)44102、金黄色葡萄球菌ATCC6538的结晶紫染色结果示意图。其中A为灭活后的裂解酶作用的大肠杆菌CMCC(B)44102菌体形态;B为裂解酶作用的大肠杆菌CMCC(B)44102菌体形态;C为灭活后的裂解酶作用的金黄色葡萄球菌ATCC6538菌体形态;D为裂解酶作用的金黄色葡萄球菌ATCC6538菌体形态;FIG. 8 is a schematic diagram of the crystal violet staining results of the action of the room temperature lyase Sly of the present invention on Escherichia coli CMCC(B)44102 and Staphylococcus aureus ATCC6538. A is the cell shape of Escherichia coli CMCC(B)44102 under the action of lyase after inactivation; B is the cell shape of Escherichia coli CMCC(B)44102 under the action of lyase; C is the shape of gold under the action of lyase after inactivation The bacterial morphology of Staphylococcus aureus ATCC6538; D is the bacterial morphology of Staphylococcus aureus ATCC6538 under the action of lyase;
图9是随着时间变化本发明常温裂解酶Sly对大肠杆菌CMCC(B)44102、金黄色葡萄球菌ATCC6538、沙门氏菌CMC(B)50094、志贺氏菌DS26菌株生长的影响。Figure 9 shows the effect of the room temperature lyase Sly of the present invention on the growth of Escherichia coli CMCC (B) 44102, Staphylococcus aureus ATCC6538, Salmonella CMC (B) 50094 and Shigella DS26 strains with time.
具体实施方式Detailed ways
下面通过实施例对本发明作进一步详细说明,但本发明的内容并不局限于此,本实施例中方法如无特殊说明的均按常规方法操作,所用试剂如无特殊说明的均采用常规试剂或按常规方法配置的试剂。The present invention will be described in further detail below through the examples, but the content of the present invention is not limited to this. The methods in this embodiment are operated by conventional methods unless otherwise specified, and the reagents used are conventional reagents or Reagents prepared according to conventional methods.
实施例1:常温裂解酶Sly的克隆和表达Example 1: Cloning and expression of room temperature lyase Sly
1、裂解酶Sly基因的扩增(以噬菌体SP26的基因组DNA为模板)1. Amplification of the lyase Sly gene (using the genomic DNA of phage SP26 as a template)
(1)常温裂解酶Sly基因的扩增所用引物序列如下:(1) The primer sequences used for the amplification of the room temperature lyase Sly gene are as follows:
正向引物:5’- CATGCCATGGCAATGGCTATTAGCAAAAACATGAAG -3’Forward primer: 5'-CATG CCATGG CAATGGCTATTAGCAAAAAACATGAAG-3'
反向引物:5’- CGGAATTCTGCCACAGCTCCGCCAGCCTCTTTA -3’Reverse primer: 5'-CG GAATTC TGCCACAGCTCCGCCAGCCTCTTTA-3'
酶切位点:Nco I和EcoR IRestriction site: Nco I and EcoR I
(2)扩增体系如下:(2) The amplification system is as follows:
表1 扩增体系组分Table 1 Components of the amplification system
; ;
(3)扩增条件如下:(3) The amplification conditions are as follows:
将反应体系混匀,先在94℃预变性10 min,然后在94℃变性45s,58℃退火45s,72℃延伸90s,30个循环后,72℃延伸10 min。扩增完后取产物5μL,在1.2%琼脂糖凝胶中进行电泳分析(见图1),PCR产物大小为465 bp。The reaction system was mixed and pre-denatured at 94 °C for 10 min, then denatured at 94 °C for 45 s, annealed at 58 °C for 45 s, extended at 72 °C for 90 s, and then extended at 72 °C for 10 min after 30 cycles. After amplification, 5 μL of the product was taken and analyzed by electrophoresis in a 1.2% agarose gel (see Figure 1). The size of the PCR product was 465 bp.
2、裂解酶Sly基因PCR产物胶回收2. Gel recovery of lyase Sly gene PCR product
(1)在电泳仪中灌制1.2%琼脂糖凝胶;(1) Cast a 1.2% agarose gel in an electrophoresis apparatus;
(2)将待分离纯化的PCR产物点样电泳,于适当位置停止电泳;(2) Spot electrophoresis of the PCR product to be separated and purified, and stop the electrophoresis at an appropriate position;
(3)在紫外灯下切下含有目的基因片段的凝胶,转移到1.5mL的EP管中;(3) Cut the gel containing the target gene fragment under UV light and transfer it to a 1.5mL EP tube;
(4)用StarPrep快速DNA胶回收试剂盒进行目的基因片段回收,回收方法按说明书进行。(4) Use the StarPrep rapid DNA gel recovery kit to recover the target gene fragments. The recovery method is carried out according to the instructions.
3、重组质粒的构建3. Construction of recombinant plasmids
为了把目的基因片段连接到质粒pET28a上,就需要使目的基因片段、质粒pET28a都带有粘性末端,即带有酶切位点。In order to connect the target gene fragment to the plasmid pET28a, it is necessary to make the target gene fragment and the plasmid pET28a have sticky ends, that is, with an enzyme cutting site.
(1)提取质粒pET28a(1) Extract plasmid pET28a
① 菌种活化:无菌接种环蘸取-80℃冻存的质粒pET28a的菌种保存液,连续化线法接种于含有卡那霉素(终浓度50µg/mL)的LB固体平板,37℃培养12~16h;① Strain activation: dip the sterile inoculation loop into the strain preservation solution of plasmid pET28a frozen at -80℃, and inoculate it on LB solid plate containing kanamycin (final concentration 50µg/mL) by continuous line method at 37℃ Culture for 12~16h;
② 富集菌液:用接种环挑取单菌落于5mL含有卡那霉素(终浓度50µg/mL)的LB液体试管中,37℃、150rpm培养12~16h;② Enriched bacterial solution: Pick a single colony with an inoculation loop and put it in a 5 mL LB liquid test tube containing kanamycin (
③ 提取质粒pET28a:用StarPrep快速质粒小提试剂盒提取质粒pET28a,提取方法按说明书进行。③ Extraction of plasmid pET28a: Extract plasmid pET28a with StarPrep Rapid Plasmid Extraction Kit, and the extraction method is carried out according to the instructions.
(2)目的基因片段及质粒pET28a的双酶切(2) Double enzyme digestion of the target gene fragment and plasmid pET28a
① 酶切体系如下:① The enzyme digestion system is as follows:
表2 酶切体系组分Table 2 Enzyme digestion system components
② 反应条件:37℃金属浴中酶切3h,回收酶切后的目的基因片段及质粒pET28a。② Reaction conditions: digested in a metal bath at 37°C for 3 hours, and recovered the target gene fragment and plasmid pET28a after digested.
(3)重组质粒的构建(3) Construction of recombinant plasmids
将带有粘性末端的目的基因片段和质粒pET28a,通过连接转化构建出重组质粒;The target gene fragment with sticky ends and the plasmid pET28a were transformed to construct a recombinant plasmid by ligation;
① 连接体系如下:① The connection system is as follows:
表3 连接体系组分Table 3 Components of the linking system
② 反应条件:16℃金属浴中连接12h,回收重组质粒。② Reaction conditions: connect in a metal bath at 16°C for 12h, and recover the recombinant plasmid.
4、重组质粒的表达4. Expression of recombinant plasmids
(1)重组质粒转化至大肠杆菌DH5α感受态细胞中(1) Transform the recombinant plasmid into E. coli DH5α competent cells
①将10μL的重组质粒转入100μL体系的感受态细胞;①Transfer 10μL of recombinant plasmid into competent cells of 100μL system;
②冰浴30min之后,42℃热击90s,再冰浴30min;②After ice bath for 30min, heat shock at 42℃ for 90s, and then ice bath for 30min;
③加入890μL LB液体培养基,37℃,100 rpm摇床培养1h;③ Add 890 μL of LB liquid medium, incubate at 37°C, 100 rpm shaker for 1 h;
④将培养后的液体培养基放入离心机中,10,000 rpm,离心10min;④Put the cultured liquid medium into a centrifuge at 10,000 rpm for 10 min;
⑤弃上清,留100μL左右将沉淀轻轻吹打混匀,涂布于含有卡那霉素(终浓度50µg/mL)的LB固体平板,37℃培养12~16h;⑤ Discard the supernatant, keep about 100 μL of the precipitate, gently pipette and mix, spread it on the LB solid plate containing kanamycin (
⑥观察上述平板的单菌落,用接种环随机挑取单菌落于5mL含有卡那霉素(终浓度50 µg/mL)的LB液体试管中,37℃、150 rpm培养12h。⑥ Observe the single colony on the above plate, randomly pick a single colony with an inoculation loop, and place it in a 5 mL LB liquid test tube containing kanamycin (
(2)双酶切验证(2) Double enzyme digestion verification
①用StarPrep快速质粒小提试剂盒提取重组质粒,提取方法按说明书进行;① Extract the recombinant plasmid with the StarPrep Rapid Plasmid Extraction Kit, and the extraction method is carried out according to the instructions;
②将提取出的重组质粒进行双酶切验证,双酶切体系如下:②Verify the extracted recombinant plasmid by double-enzyme digestion. The double-enzyme digestion system is as follows:
表4 双酶切体系组分Table 4 Components of double enzyme digestion system
反应条件:37℃金属浴中酶切3h,回收酶切后的重组质粒并进行电泳验证(见图2)。Reaction conditions: Enzymatic digestion was performed in a metal bath at 37°C for 3 hours, and the recombinant plasmids after digestion were recovered and verified by electrophoresis (see Figure 2).
(3)重组质粒转化至E. coli Rosetta菌株(3) Transform the recombinant plasmid into E. coli Rosetta strain
将验证正确的重组质粒转入E. coli Rosetta菌株中,方法同上;即可得到表达菌株pET28a-Sly/Rosetta。Transfer the verified correct recombinant plasmid into E. coli Rosetta strain, the method is the same as above; the expression strain pET28a-Sly/Rosetta can be obtained.
5、重组蛋白的诱导表达及纯化5. Induction, expression and purification of recombinant protein
①将表达菌株pET28a-Sly/Rosetta接种至5mL含有卡那霉素(终浓度50µg/mL)的LB液体试管中,37℃、150rpm培养至OD600值为0.6~0.8;①Inoculate the expression strain pET28a-Sly/Rosetta into 5mL LB liquid test tube containing kanamycin (final concentration 50µg/mL), and cultivate it at 37℃ and 150rpm until the OD 600 value is 0.6~0.8;
②按1%比例接种上述菌液至600mL含有卡那霉素(终浓度50µg/mL)的LB液体试管中,37℃、150rpm培养至OD600值为1.0~1.2;再加入诱导剂乳糖(终浓度1g/L)至表达菌株的菌液中,放置于37℃、150rpm分别诱导6、8、10、12 h;
③诱导后的菌液于4℃、9000rpm离心8min后留沉淀,加适量ddH2O吹打混匀后于4℃,9000rpm离心10min后留沉淀,按100:1的比例用PBS缓冲液吹打混匀后进行超声波破碎;③ After the induced bacterial solution was centrifuged at 4°C and 9000rpm for 8min, the precipitate was left. Add an appropriate amount of ddH 2 O to mix by blowing and beating. After centrifugation at 4°C and 9000rpm for 10min, the precipitate was left. The PBS buffer was mixed at a ratio of 100:1. After ultrasonic crushing;
④超声波破碎:功率为35%,工作3s,停4s,每管60~90min,破碎至透光,取80µL全蛋白于已灭菌的EP管内。剩余全蛋白于13,000 rpm,离心10min取上清,上清分装于已灭菌的EP管内;④Ultrasonic crushing: the power is 35%, work for 3s, stop for 4s, 60~90min per tube, crush until light is transparent, take 80µL of whole protein into a sterilized EP tube. The remaining whole protein was centrifuged at 13,000 rpm for 10 min to get the supernatant, and the supernatant was divided into sterilized EP tubes;
⑤SDS-PAGE电泳检测表达结果(见图3),目的蛋白在37℃、150rpm,1g/L乳糖诱导12 h条件下,表达效果最好;因此诱导最佳条件为37℃,150rpm,1g/L乳糖诱导12h;⑤ The expression results were detected by SDS-PAGE electrophoresis (see Figure 3). The expression of the target protein was the best at 37°C, 150rpm, and 1g/L lactose for 12 h. Therefore, the best induction conditions were 37°C, 150rpm, 1g/L. Lactose induction for 12h;
⑥最佳条件诱导后使用AKTA prime蛋白质纯化系统进行纯化,纯化后进行SDS-PAGE电泳检测纯化结果(见图4);结果说明裂解酶Sly的洗脱条带单一且表达量较高,说明纯化成功。⑥ After induction under optimal conditions, AKTA prime protein purification system was used for purification, and SDS-PAGE electrophoresis was used to detect the purification results (see Figure 4); the results showed that the elution band of lyase Sly was single and the expression level was high, indicating purification success.
实施例2:常温裂解酶Sly的酶学性质及酶活性实验Example 2: Enzymatic properties and enzymatic activity experiments of room temperature lyase Sly
1、裂解酶Sly蛋白的浓度及酶活力测定1. Determination of lyase Sly protein concentration and enzyme activity
(1)采用BCA(Bicinchoninic Acid)蛋白浓度检测法测定蛋白浓度(1) Determination of protein concentration by BCA (Bicinchoninic Acid) protein concentration detection method
在碱性条件下,利用Cu2+可以被蛋白质还原成Cu+,Cu+与BCA试剂结合形成紫色的络合物的特性,通过测定样品在590 nm波长下的OD值,并同蛋白标准曲线对比,即可计算出待测样品的蛋白浓度。Under alkaline conditions, Cu 2+ can be reduced to Cu + by protein, and Cu + combines with BCA reagent to form a purple complex. By measuring the OD value of the sample at a wavelength of 590 nm, and comparing it with the protein standard curve By comparison, the protein concentration of the sample to be tested can be calculated.
按照BCA蛋白质定量试剂盒说明书中的“微量法”进行,用酶标仪测定590nm波长处的OD值。以蛋白浓度为横坐标,OD590值为纵坐标,绘制标准曲线,得到的标准曲线方程为:y= 0.0009x+0.006(R2 = 0.9914)。According to the "micro method" in the instructions of the BCA protein quantification kit, the OD value at the wavelength of 590nm was measured with a microplate reader. Taking the protein concentration as the abscissa and the OD 590 value as the ordinate, draw the standard curve, and the obtained standard curve equation is: y= 0.0009x+0.006 (R 2 = 0.9914).
(2)采用福林酚法测定酶活力(2) Determination of enzyme activity by Folin phenol method
在碱性条件下,福林酚试剂可被酚类化合物还原,生成蓝色化合物。而蛋白酶在最适作用温度和最适作用pH值的条件下,水解酪蛋白底物,会产生含有酚基的氨基酸(如:酪氨酸、色氨酸等)。因此可利用此原理测定酶活力。Under alkaline conditions, the Folin phenol reagent can be reduced by phenolic compounds to form blue compounds. The protease hydrolyzes the casein substrate under the conditions of the optimum temperature and pH, and produces amino acids containing phenolic groups (such as: tyrosine, tryptophan, etc.). Therefore, this principle can be used to measure enzyme activity.
酶活力单位定义:在一定温度和pH值条件下,酶液在1min内水解酪蛋白底物产生1μg酪氨酸为一个酶活力单位,以U表示。The definition of enzyme activity unit: Under certain temperature and pH value conditions, the enzyme solution hydrolyzes the casein substrate within 1min to produce 1 μg of tyrosine as an enzyme activity unit, which is represented by U.
①试剂及溶液①Reagents and solutions
福林酚试剂、0.4mol/L的碳酸钠溶液、0.4mol/L三氯乙酸溶液、pH值为7.2的磷酸盐缓冲液、2%酪蛋白溶液、100μg/mL酪氨酸溶液。Folin phenol reagent, 0.4mol/L sodium carbonate solution, 0.4mol/L trichloroacetic acid solution, pH 7.2 phosphate buffer, 2% casein solution, 100 μg/mL tyrosine solution.
②标准曲线的绘制②Drawing of standard curve
按表5配制不同浓度的酪氨酸溶液Prepare tyrosine solutions of different concentrations according to Table 5
表5 不同浓度酪氨酸溶液的配制方法Table 5 Preparation methods of tyrosine solutions with different concentrations
测定步骤:分别吸取上表中不同浓度的酪氨酸溶液1mL,各加入0.4 mol/L碳酸钠溶液5mL,再加入福林酚试剂1mL;摇匀后放置于40℃水浴锅中,保温发色20min,酶标仪测量OD680值并记录。以酪氨酸质量为横坐标,OD680值为纵坐标,绘制标准曲线,得到的标准曲线方程:y=0.003x+0.0099(R2=0.9959)。Determination steps: draw 1 mL of tyrosine solutions of different concentrations in the table above, add 5 mL of 0.4 mol/L sodium carbonate solution to each, and then add 1 mL of Folin phenol reagent; shake well and place in a 40°C water bath, keep warm for color development 20min, the microplate reader measures the OD 680 value and records. Taking the mass of tyrosine as the abscissa and the OD 680 value as the ordinate, draw a standard curve, and the obtained standard curve equation: y=0.003x+0.0099 (R 2 =0.9959).
③酶活力测定步骤③ Enzyme activity determination steps
吸取酶液的稀释液(浓度为46.67μg/mL)2mL,置于40℃水浴锅中预热2min,然后加入经同样预热后的2%酪蛋白溶液1mL,40℃水浴锅中精确保温5min。时间到后,立即加入0.4mol/L三氯乙酸溶液1mL,以终止反应,继续置于40℃水浴锅中保温20min,使残余蛋白质沉淀。吸取含有沉淀的溶液,使用0.22μm滤膜过滤溶液,然后吸取滤液1mL,再加入0.4mol/L碳酸钠溶液5mL,福林酚试剂1mL摇匀,40℃水浴锅中保温发色20min后测量OD680值。
测得裂解酶OD680值为0.317,将OD680值代入标准曲线方程:y = 0.003x + 0.0099(R2 = 0.9959),计算得到酪氨酸质量为102.37μg。将酪氨酸质量代入公式:Y=(A×N)/(V×t)(Y:样品的酶活力,U;A:酪氨酸质量,μg;N:样品的稀释倍数;V:反应试剂的总体积,mL;t:反应时间,min),计算得到酶活力Y=(102.37×5)/(4×5)=25.59 U。The OD 680 value of the lyase was determined to be 0.317, and the OD 680 value was substituted into the standard curve equation: y = 0.003x + 0.0099 (R 2 = 0.9959), and the calculated mass of tyrosine was 102.37 μg. Substitute the mass of tyrosine into the formula: Y=(A×N)/(V×t) (Y: enzyme activity of the sample, U; A: mass of tyrosine, μg; N: dilution ratio of the sample; V: reaction The total volume of the reagents, mL; t: reaction time, min), the calculated enzyme activity Y=(102.37×5)/(4×5)=25.59 U.
2、不同作用温度、pH值及金属离子对常温裂解酶Sly的影响2. The effect of different temperature, pH value and metal ions on the room temperature lyase Sly
裂解酶可以水解肽聚糖,肽聚糖被水解后,会导致反应底物OD600值显著下降;酶活性越高,OD600值下降的程度则越大,因此反应底物OD600值的变化可用于评价裂解酶的活性。Lyases can hydrolyze peptidoglycan. After peptidoglycan is hydrolyzed, the OD 600 value of the reaction substrate will decrease significantly; the higher the enzyme activity, the greater the decrease in the OD 600 value, so the change in the OD 600 value of the reaction substrate Can be used to evaluate lyase activity.
酶活(%)=[(OD600反应前-OD600反应后)/初始OD600]×100Enzyme activity (%)=[( before OD 600 reaction - after OD 600 reaction)/initial OD 600 ]×100
将测得的最高酶活设为100%,相对酶活(%)=(其他温度下的酶活/最高酶活)×100。Set the highest enzyme activity measured as 100%, relative enzyme activity (%) = (enzyme activity at other temperatures/maximum enzyme activity) × 100.
(1)制备反应底物(1) Preparation of reaction substrates
①用无菌接种环蘸取-80℃冻存的宿主菌DS26的菌种保存液,连续化线法接种于LB固体平板上,37℃培养12~16h;① Dip the strain preservation solution of host bacteria DS26 frozen at -80°C with a sterile inoculation loop, inoculate it on LB solid plate by continuous line method, and cultivate at 37°C for 12~16h;
②用无菌接种环挑取上述平板的单菌落于5mL LB液体试管中,37℃、150rpm培养至OD600值为0.6~0.8,按1%比例接种菌液至600mL LB液体试管中,37℃、150rpm培养至OD600值为1.0~1.2;②Pick a single colony on the above plate with a sterile inoculating loop and put it in a 5mL LB liquid test tube, incubate at 37°C and 150rpm until the OD 600 value is 0.6~0.8, and inoculate the bacterial liquid at a ratio of 1% into a 600mL LB liquid test tube, at 37°C , 150rpm culture to OD 600 value of 1.0~1.2;
③将上述菌液于9000rpm离心10min后,弃上清。沉淀以10mL ddH2O吹打混匀后,超声波破碎(功率为35%,工作3s,停4s,总时间120min),13000rpm离心10min得沉淀。将沉淀重新使用10mL ddH2O吹打混匀;此时宿主菌DS26的细胞壁均为细胞碎片,作为以下实验的反应底物。③ After centrifuging the above bacterial solution at 9000rpm for 10min, discard the supernatant. After the precipitate was mixed with 10 mL of ddH 2 O by blowing and beating, ultrasonically disrupted (power was 35%, working for 3 s, stopping for 4 s,
(2)常温裂解酶Sly的最适作用温度(2) The optimum temperature for the action of the lyase Sly at room temperature
将纯化后的裂解酶Sly(浓度为135.56μg/mL)加入制备好的反应底物中,然后置于不同温度反应30min,反应温度分别是4℃、20℃、30℃、35℃、37℃、40℃、45℃、50℃、60℃、70℃。其中,反应底物的初始OD600=0.365,根据反应前后OD600的变化量确定其最适温度(见图5)。The purified lyase Sly (concentration of 135.56 μg/mL) was added to the prepared reaction substrate, and then placed at different temperatures for 30 min. The reaction temperatures were 4 °C, 20 °C, 30 °C, 35 °C, and 37 °C. , 40℃, 45℃, 50℃, 60℃, 70℃. Among them, the initial OD 600 of the reaction substrate is 0.365, and the optimum temperature is determined according to the change of OD 600 before and after the reaction (see Figure 5).
由图5分析可知,该裂解酶最适作用温度为37℃,在30℃~45℃之间酶活较高。It can be seen from the analysis in Figure 5 that the optimal temperature of the lyase is 37 °C, and the enzyme activity is higher between 30 °C and 45 °C.
(3)常温裂解酶Sly的最适作用pH值(3) The optimum pH value of room temperature lyase Sly
将纯化后的裂解酶Sly(浓度为135.56μg/mL)加入制备好的反应底物中,在最适作用温度下,分别在不同pH值的磷酸盐缓冲液中,反应30min,测定反应前后OD600值,其中反应底物的初始OD600=0.295,根据反应前后OD600的变化量确定其最适pH值(见图6)。The purified lyase Sly (concentration of 135.56 μg/mL) was added to the prepared reaction substrate, and at the optimum temperature, the reaction was carried out in phosphate buffers with different pH values for 30 min, and the OD before and after the reaction was measured. 600 value, where the initial OD 600 of the reaction substrate = 0.295, and its optimum pH value was determined according to the change in OD 600 before and after the reaction (see Figure 6).
由图6分析可知,该裂解酶最适作用pH值为7.5,pH值在6~10之间酶活较高。It can be seen from the analysis in Figure 6 that the optimal pH value of the lyase is 7.5, and the enzyme activity is higher between
(4)不同金属离子对酶活的影响(4) Effects of different metal ions on enzyme activity
将纯化后的裂解酶Sly(浓度为145.56μg/mL)加入制备好的反应底物中,混合液中加入不同金属离子Mn2+、Ca2+、Mg2+、Zn2+、Fe3+、Na+、K+,并保持离子浓度为1mmol/L,在最适作用温度和最适pH值条件下,反应30min,测定反应前后OD600值,其中反应底物的初始OD600=0.411,对照组使用ddH2O代替金属离子。我们把能提高酶活的金属离子称为酶的激活剂,反之,则称酶的抑制剂(见图7)。The purified lyase Sly (concentration of 145.56μg/mL) was added to the prepared reaction substrate, and different metal ions Mn 2+ , Ca 2+ , Mg 2+ , Zn 2+ , Fe 3+ were added to the mixture. , Na + , K + , and keep the ion concentration at 1 mmol/L, under the conditions of the optimum temperature and pH value, react for 30 min, and measure the OD 600 value before and after the reaction, wherein the initial OD 600 of the reaction substrate =0.411, The control group used ddH 2 O instead of metal ions. We call the metal ions that can increase the enzyme activity as enzyme activators, and vice versa, as enzyme inhibitors (see Figure 7).
由图7可以看出,Mg2+、Na+、K+这三种离子对酶有激活作用,Zn2+、Mn2+、Fe3+这三种离子对酶有抑制作用,而Ca2+对酶的影响不大。It can be seen from Figure 7 that the three ions Mg 2+ , Na + , and K + have an activating effect on the enzyme, and the three ions Zn 2+ , Mn 2+ , and Fe 3+ have an inhibitory effect on the enzyme, while Ca 2 + Little effect on enzymes.
3、常温裂解酶Sly作用于大肠杆菌CMCC(B)44102、金黄色葡萄球菌ATCC6538的结晶紫染色结果3. Crystal violet staining results of room temperature lyase Sly acting on Escherichia coli CMCC(B)44102 and Staphylococcus aureus ATCC6538
将大肠杆菌CMCC(B)44102、金黄色葡萄球菌ATCC6538培养至OD600值分别为0.531、0.519,菌液8000rpm离心10min得到菌体,以ddH2O洗涤3次,收集菌体,用PBS进行稀释,然后100µL菌液(2.37×103 CFU/mL)中加入900µL裂解酶Sly(浓度为141.11μg/mL),37℃反应30min,用草酸铵结晶紫染色液染色、制片后于光学显微镜下进行镜检(见图8),对照采用121℃、灭活20min的酶液;Escherichia coli CMCC (B) 44102 and Staphylococcus aureus ATCC6538 were cultured to OD 600 values of 0.531 and 0.519, respectively, and the bacterial solution was centrifuged at 8000 rpm for 10 min to obtain bacterial cells, washed three times with ddH 2 O, collected and diluted with PBS. , and then 900µL of lyase Sly (concentration of 141.11µg/mL) was added to 100µL bacterial solution (2.37×10 3 CFU/mL), reacted at 37°C for 30min, stained with ammonium oxalate crystal violet staining solution, sliced and placed under a light microscope Perform microscopic examination (see Figure 8), and use the enzyme solution at 121°C for 20 minutes of inactivation as the control;
由图8可以看出,裂解酶Sly作用的大肠杆菌CMCC(B)44102、金黄色葡萄球菌ATCC6538的部分菌体形态不能被结晶紫染色液染色,说明这部分已被裂解酶Sly裂解;而灭活后的酶液作用的大肠杆菌CMCC(B)44102、金黄色葡萄球菌ATCC6538的菌体形态无明显变化。It can be seen from Fig. 8 that the cell morphology of Escherichia coli CMCC (B) 44102 and Staphylococcus aureus ATCC6538 acted by lyase Sly cannot be stained by crystal violet staining solution, indicating that this part has been lysed by lyase Sly; The bacterial morphology of Escherichia coli CMCC(B)44102 and Staphylococcus aureus ATCC6538 treated with the live enzyme solution did not change significantly.
4、随着时间变化常温裂解酶Sly对大肠杆菌CMCC(B)44102、金黄色葡萄球菌ATCC6538、志贺氏菌DS26、沙门氏菌CMC(B)50094菌株生长的影响4. The effect of normal temperature lyase Sly on the growth of Escherichia coli CMCC(B)44102, Staphylococcus aureus ATCC6538, Shigella DS26 and Salmonella CMC(B)50094 strains with time
按1%接种量,接种大肠杆菌CMCC(B)44102、金黄色葡萄球菌ATCC6538、志贺氏菌DS26、沙门氏菌CMC(B)50094的菌液到LB液体培养基中,37℃、150rpm培养至OD600值分别为0.506、0.522、0.537、0.525。将酶液(浓度为252.22μg/mL)用已灭菌0.22μm滤膜过滤后,加入Mg2+、Na+、K+(终浓度均为1mmol/L),吸取270μL酶液分别与30μL大肠杆菌CMCC(B)44102菌液(1.12×103 CFU/mL)、金黄色葡萄球菌ATCC6538菌液(1.43×103 CFU/mL)、志贺氏菌DS26菌液(1.08×103 CFU/mL)、沙门氏菌CMC(B)50094菌液(1.67×103 CFU/mL)混合,混合液于37℃恒温培养箱反应0、10、20、30、40、50、60min后,取50μL反应后的混合液涂布平板,对照采用121℃、灭活20min的酶液;涂布之后放置于37℃恒温培养箱过夜培养,统计实验组与对照组的活细胞数,计算抗菌活性。(注:每组各3个平行)抗菌活性定义为对数相对失活单位log10(N0/Ni),N0为灭活酶液处理的活细胞数(对照组),Ni为酶液处理后的活细胞数(实验组);According to 1% inoculation amount, inoculate the bacterial liquid of Escherichia coli CMCC(B)44102, Staphylococcus aureus ATCC6538, Shigella DS26, Salmonella CMC(B)50094 into LB liquid medium, and cultivate to OD at 37°C and 150rpm. The 600 values are 0.506, 0.522, 0.537, 0.525, respectively. The enzyme solution (concentration of 252.22 μg/mL) was filtered through a sterilized 0.22 μm filter, and Mg 2+ , Na + , K + (the final concentration was all 1 mmol/L) were added, and 270 μL of the enzyme solution and 30 μL of the large intestine were drawn. Bacillus CMCC(B)44102 (1.12×10 3 CFU/mL), Staphylococcus aureus ATCC6538 (1.43×10 3 CFU/mL), Shigella DS26 (1.08×10 3 CFU/mL) ) and Salmonella CMC(B) 50094 bacterial solution (1.67×10 3 CFU/mL), the mixture was reacted in a constant temperature incubator at 37°C for 0, 10, 20, 30, 40, 50, and 60 min, and 50 μL of the reacted The mixture was coated on the plate, and the enzyme solution was inactivated at 121 °C for 20 min as the control; after coating, it was placed in a constant temperature incubator at 37 °C for overnight incubation, and the number of viable cells in the experimental group and the control group was counted to calculate the antibacterial activity. (Note: 3 parallels in each group) Antibacterial activity is defined as logarithmic relative inactivation unit log 10 (N0/Ni), N0 is the number of live cells treated with inactivated enzyme solution (control group), and Ni is after enzyme solution treatment The number of viable cells (experimental group);
由图9可知:在酶浓度和菌浓度一定的情况下,随着时间变化,裂解酶Sly对菌株的杀伤作用随之变化。当作用时间为10 min时,大肠杆菌CMCC(B)44102的活细胞数减少最多,志贺氏菌DS26、沙门氏菌CMC(B)50094活细胞数减少次之,对金黄色葡萄球菌ATCC6538的活细胞数减少相对较少。总之,此裂解酶对革兰氏阳性和阴性细菌均具有一定的杀灭作用。It can be seen from Fig. 9 that the killing effect of the lyase Sly on the strain changes with the change of time when the enzyme concentration and the bacterial concentration are constant. When the action time was 10 min, the number of viable cells of Escherichia coli CMCC(B)44102 decreased the most, followed by that of Shigella DS26 and Salmonella CMC(B)50094, and the number of viable cells of Staphylococcus aureus ATCC6538 decreased the second. The decrease is relatively small. In conclusion, this lyase has a certain killing effect on both Gram-positive and negative bacteria.
序列表sequence listing
<110> 昆明理工大学<110> Kunming University of Science and Technology
<120> 一种常温裂解酶Sly和编码此酶的多核苷酸<120> A room temperature lyase Sly and a polynucleotide encoding the enzyme
<160> 4<160> 4
<170> SIPOSequenceListing 1.0<170> SIPOSequenceListing 1.0
<210> 1<210> 1
<211> 154<211> 154
<212> PRT<212> PRT
<213> 噬菌体SP26(Phage SP26)<213> Phage SP26 (Phage SP26)
<400> 1<400> 1
Met Ala Ile Ser Lys Asn Met Lys Ala Phe Leu Asp Met Leu Ala TyrMet Ala Ile Ser Lys Asn Met Lys Ala Phe Leu Asp Met Leu Ala Tyr
1 5 10 151 5 10 15
Ser Glu Gly Thr Asp Asn Gly Arg Gln Lys Thr Asn Asn His Gly TyrSer Glu Gly Thr Asp Asn Gly Arg Gln Lys Thr Asn Asn His Gly Tyr
20 25 30 20 25 30
Asp Val Ile Val Gly Gly Ser Leu Phe Thr Asp Tyr Ser Asp His ProAsp Val Ile Val Gly Gly Ser Leu Phe Thr Asp Tyr Ser Asp His Pro
35 40 45 35 40 45
Arg Lys Leu Ile Ser Leu Pro Lys Leu Gly Ile Lys Ser Thr Ala AlaArg Lys Leu Ile Ser Leu Pro Lys Leu Gly Ile Lys Ser Thr Ala Ala
50 55 60 50 55 60
Gly Arg Tyr Gln Val Leu Ala Lys Phe Tyr Asp Ala Tyr Lys Lys GlnGly Arg Tyr Gln Val Leu Ala Lys Phe Tyr Asp Ala Tyr Lys Lys Gln
65 70 75 8065 70 75 80
Leu Arg Leu Pro Asp Phe Ser Pro Thr Ser Gln Asp Ala Ile Ala MetLeu Arg Leu Pro Asp Phe Ser Pro Thr Ser Gln Asp Ala Ile Ala Met
85 90 95 85 90 95
Gln Leu Ile Arg Glu Cys Lys Ala Thr Ala Asp Ile Glu Ala Gly ArgGln Leu Ile Arg Glu Cys Lys Ala Thr Ala Asp Ile Glu Ala Gly Arg
100 105 110 100 105 110
Ile Ala Asp Ala Ile His Lys Cys Arg Ser Arg Trp Ala Ser Leu ProIle Ala Asp Ala Ile His Lys Cys Arg Ser Arg Trp Ala Ser Leu Pro
115 120 125 115 120 125
Gly Ala Gly Tyr Gly Gln His Glu Gln Lys Leu Asp Lys Leu Ile GlnGly Ala Gly Tyr Gly Gln His Glu Gln Lys Leu Asp Lys Leu Ile Gln
130 135 140 130 135 140
Val Tyr Lys Glu Ala Gly Gly Ala Val AlaVal Tyr Lys Glu Ala Gly Gly Ala Val Ala
145 150145 150
<210> 2<210> 2
<211> 465<211> 465
<212> DNA<212> DNA
<213> 噬菌体SP26(Phage SP26)<213> Phage SP26 (Phage SP26)
<400> 2<400> 2
atggctatta gcaaaaacat gaaggcgttt ctggatatgc tggcgtacag cgagggcacg 60atggctatta gcaaaaacat gaaggcgttt ctggatatgc tggcgtacag cgagggcacg 60
gataacgggc ggcagaaaac caataatcat ggctatgatg tgattgttgg tggctcactg 120gataacgggc ggcagaaaac caataatcat ggctatgatg tgattgttgg tggctcactg 120
tttaccgact attccgacca cccgcgcaaa ctgattagcc tgcctaagct gggcatcaaa 180tttaccgact attccgacca cccgcgcaaa ctgattagcc tgcctaagct gggcatcaaa 180
tccaccgccg ccgggcgata tcaggtgctg gctaagtttt atgatgcgta caaaaagcag 240tccaccgccg ccgggcgata tcaggtgctg gctaagtttt atgatgcgta caaaaagcag 240
ttgcgtttgc cggacttctc cccaacatcg caggacgcta ttgcaatgca gctaatccgt 300ttgcgtttgc cggacttctc cccaacatcg caggacgcta ttgcaatgca gctaatccgt 300
gaatgcaagg ccaccgccga tattgaagct ggtcgcattg ctgatgctat tcataaatgc 360gaatgcaagg ccaccgccga tattgaagct ggtcgcattg ctgatgctat tcataaatgc 360
cgctcccgct gggcttcatt gccgggtgct ggttatggtc agcacgaaca gaaactggat 420cgctcccgct gggcttcatt gccgggtgct ggttatggtc agcacgaaca gaaactggat 420
aagctgattc aggtatataa agaggctggc ggagctgtgg catga 465aagctgattc aggtatataa agaggctggc ggagctgtgg catga 465
<210> 3<210> 3
<211> 36<211> 36
<212> DNA<212> DNA
<213> 人工序列(Artificial)<213> Artificial Sequence (Artificial)
<400> 3<400> 3
catgccatgg caatggctat tagcaaaaac atgaag 36catgccatgg caatggctat tagcaaaaac atgaag 36
<210> 4<210> 4
<211> 33<211> 33
<212> DNA<212> DNA
<213> 人工序列(Artificial)<213> Artificial Sequence (Artificial)
<400> 4<400> 4
cggaattctg ccacagctcc gccagcctct tta 33cggaattctg ccacagctcc gccagcctct tta 33
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010780549.2A CN111876400B (en) | 2020-08-06 | 2020-08-06 | Normal temperature lyase Sly and polynucleotide for coding same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010780549.2A CN111876400B (en) | 2020-08-06 | 2020-08-06 | Normal temperature lyase Sly and polynucleotide for coding same |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111876400A CN111876400A (en) | 2020-11-03 |
CN111876400B true CN111876400B (en) | 2022-05-24 |
Family
ID=73210971
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010780549.2A Active CN111876400B (en) | 2020-08-06 | 2020-08-06 | Normal temperature lyase Sly and polynucleotide for coding same |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111876400B (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112143747B (en) * | 2020-09-09 | 2022-09-13 | 昆明理工大学 | A kind of bacteriophage lyase and its gene, gene recombinant expression vector and application |
CN115094051B (en) * | 2022-04-08 | 2023-09-22 | 福建福大百特生物科技有限公司 | Recombinant lysozyme from bemyces fumosoroseus as well as preparation method and application thereof |
Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1329509A (en) * | 1998-10-20 | 2002-01-02 | 阿维根公司 | Adeno-associated vectors for expression of factor VIII target cells |
US7033781B1 (en) * | 1999-09-29 | 2006-04-25 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
US7217788B2 (en) * | 1996-03-14 | 2007-05-15 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta polypeptides |
CN101208099A (en) * | 2004-07-21 | 2008-06-25 | Ambrx公司 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
CN102186878A (en) * | 2008-08-19 | 2011-09-14 | 拜奥默里克斯公司 | Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins |
CN106796222A (en) * | 2014-06-20 | 2017-05-31 | 乌尔里希·洛斯 | Detection of autoantibodies against the TSH receptor |
CN107794254A (en) * | 2017-09-30 | 2018-03-13 | 昆明理工大学 | The method for quickly purifying of recombinant high temperature lyases |
CN107828769A (en) * | 2017-09-28 | 2018-03-23 | 昆明理工大学 | A kind of heat-resisting lyases MMPpgh and the polynucleotides for encoding this enzyme |
CN107922565A (en) * | 2015-06-23 | 2018-04-17 | 菲吉乐科(加拿大)有限公司 | Composition comprising amino acid polymer and bioactivator and preparation method thereof |
CN108486089A (en) * | 2018-04-16 | 2018-09-04 | 中国水产科学研究院黄海水产研究所 | Derived from the wide range lyases and its antibacterial applications of salmonella bacteriophage |
CN110079508A (en) * | 2019-05-10 | 2019-08-02 | 上海瑞宙生物科技有限公司 | A kind of bacteriophage, depolymerase of phage expression and its preparation method and application |
CN110592056A (en) * | 2019-09-19 | 2019-12-20 | 昆明理工大学 | Phage lyase compound powder and its preparation method and application |
CN110592057A (en) * | 2019-09-27 | 2019-12-20 | 昆明理工大学 | Chimeric lyase ILTphg and polynucleotide encoding the enzyme |
CN110891612A (en) * | 2017-06-21 | 2020-03-17 | Xl-蛋白有限责任公司 | Conjugates of protein drugs and P/A peptides |
CN110951715A (en) * | 2019-12-28 | 2020-04-03 | 王中华 | Staphylococcus-resistant broad-spectrum phage coding lyase and preparation method and application thereof |
CN111655841A (en) * | 2017-06-21 | 2020-09-11 | 同生运营公司 | Bacteria for treating disorders |
CN112143747A (en) * | 2020-09-09 | 2020-12-29 | 昆明理工大学 | Phage lyase, gene thereof, gene recombination expression vector and application |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994028139A1 (en) * | 1993-05-28 | 1994-12-08 | Massachusetts Institute Of Technology | tRNA BINDING-DEPENDENT INHIBITION OF MICROBIAL PATHOGEN GROWTH |
US5976792A (en) * | 1994-05-24 | 1999-11-02 | Siga Pharmaceuticals, Inc. | Regulation of exoprotein in staphylococcus aureus |
US20020120116A1 (en) * | 1998-05-04 | 2002-08-29 | Charles A. Kunsch | Enterococcus faecalis polynucleotides and polypeptides |
CA2417188A1 (en) * | 2000-07-25 | 2002-01-31 | Carl R. Merril | Bacteriophage having multiple host range |
WO2008080900A2 (en) * | 2006-12-29 | 2008-07-10 | Evonik Degussa Gmbh | Methionine synthases with reduced product inhibition |
EP3714895A3 (en) * | 2009-06-26 | 2020-11-25 | Lysando AG | Antimicrobial agents |
EP2563916B1 (en) * | 2010-04-27 | 2015-07-08 | Lysando AG | Method of reducing biofilms |
WO2013089890A2 (en) * | 2011-09-30 | 2013-06-20 | Mascoma Corporation | Engineering microorganisms to increase ethanol production by metabolic redirection |
EP3852778A2 (en) * | 2018-09-17 | 2021-07-28 | Universiteit Leiden | Bioactive peptides derived from snakes |
WO2021178968A1 (en) * | 2020-03-06 | 2021-09-10 | Endolytix Technology, Inc. | Compositions and methods for the treatment of intracellular bacterial infections |
-
2020
- 2020-08-06 CN CN202010780549.2A patent/CN111876400B/en active Active
Patent Citations (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7217788B2 (en) * | 1996-03-14 | 2007-05-15 | Human Genome Sciences, Inc. | Human tumor necrosis factor delta polypeptides |
CN1329509A (en) * | 1998-10-20 | 2002-01-02 | 阿维根公司 | Adeno-associated vectors for expression of factor VIII target cells |
US7033781B1 (en) * | 1999-09-29 | 2006-04-25 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
CN101208099A (en) * | 2004-07-21 | 2008-06-25 | Ambrx公司 | Biosynthetic polypeptides utilizing non-naturally encoded amino acids |
CN102186878A (en) * | 2008-08-19 | 2011-09-14 | 拜奥默里克斯公司 | Artificial peptidoglycan lysing enzymes and peptidoglycan binding proteins |
CN106796222A (en) * | 2014-06-20 | 2017-05-31 | 乌尔里希·洛斯 | Detection of autoantibodies against the TSH receptor |
CN107922565A (en) * | 2015-06-23 | 2018-04-17 | 菲吉乐科(加拿大)有限公司 | Composition comprising amino acid polymer and bioactivator and preparation method thereof |
CN110891612A (en) * | 2017-06-21 | 2020-03-17 | Xl-蛋白有限责任公司 | Conjugates of protein drugs and P/A peptides |
CN111655841A (en) * | 2017-06-21 | 2020-09-11 | 同生运营公司 | Bacteria for treating disorders |
CN107828769A (en) * | 2017-09-28 | 2018-03-23 | 昆明理工大学 | A kind of heat-resisting lyases MMPpgh and the polynucleotides for encoding this enzyme |
CN107794254A (en) * | 2017-09-30 | 2018-03-13 | 昆明理工大学 | The method for quickly purifying of recombinant high temperature lyases |
CN108486089A (en) * | 2018-04-16 | 2018-09-04 | 中国水产科学研究院黄海水产研究所 | Derived from the wide range lyases and its antibacterial applications of salmonella bacteriophage |
CN110079508A (en) * | 2019-05-10 | 2019-08-02 | 上海瑞宙生物科技有限公司 | A kind of bacteriophage, depolymerase of phage expression and its preparation method and application |
CN110592056A (en) * | 2019-09-19 | 2019-12-20 | 昆明理工大学 | Phage lyase compound powder and its preparation method and application |
CN110592057A (en) * | 2019-09-27 | 2019-12-20 | 昆明理工大学 | Chimeric lyase ILTphg and polynucleotide encoding the enzyme |
CN110951715A (en) * | 2019-12-28 | 2020-04-03 | 王中华 | Staphylococcus-resistant broad-spectrum phage coding lyase and preparation method and application thereof |
CN112143747A (en) * | 2020-09-09 | 2020-12-29 | 昆明理工大学 | Phage lyase, gene thereof, gene recombination expression vector and application |
Non-Patent Citations (6)
Title |
---|
"Learning from Bacteriophages - Advantages and Limitations of Phage and Phage-Encoded Protein Applications";Zuzanna Drulis-Kawa等;《Current Protein and Peptide Science》;20121231(第13期);第699-722页 * |
"lysin [Salmonella phage 64795_sal3]";Paradiso,R.等;《Genbank Database》;20180813;Accession No:YP_009322207.1 * |
"lysozyme [Shigella phage DS8]";Deng,Z.等;《Genbank Databse》;20210502;Accession No:YP_010054248.1 * |
"Shigella phage DS8, complete genome";Deng,Z.等;《Genbank Database》;20210502;Accession No:NC_054650.1 * |
"噬菌体裂解酶作用机制及用于细菌感染治疗的研究进展";朱丹等;《基础医学与临床》;20180129;第38卷(第2期);第241-245页 * |
"噬菌体裂解酶的抗菌特性";王琰等;《微生物学报》;20091004;第49卷(第10期);第1277-1281页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111876400A (en) | 2020-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112143747B (en) | A kind of bacteriophage lyase and its gene, gene recombinant expression vector and application | |
CN113549610B (en) | Antibacterial peptide P104 with broad-spectrum lytic activity, lyase LysP53 and application thereof | |
CN111876400B (en) | Normal temperature lyase Sly and polynucleotide for coding same | |
CN103436514A (en) | Heat-resistant lyase TSPpgh and polynucleotide coding same | |
EP3299459B1 (en) | Staphylococcus lyase and use thereof | |
AU2020102182A4 (en) | CHIMERIC LYSIN ILTphg AND POLYNUCLEOTIDE FOR ENCODING THE SAME | |
CN107828769B (en) | Heat-resistant lyase MMPpgh and polynucleotide for encoding same | |
CN107098953A (en) | Chitin-binding protein Bt CBP and its encoding gene and preparation method and application | |
CN119060987A (en) | Use of bacteriophage depolymerase dep253 in degrading bacterial capsular polysaccharides | |
CN114807106B (en) | Application of lyase pEf and perforin protein pEf191 | |
CN114634891B (en) | A Strain of Bacillus Velez ZH3 and Its Application | |
CN112574972B (en) | Bacillus belgii AiiA-homologous lactonase, gene and application thereof | |
CN108752431A (en) | Heterozygous antibacterial peptide Mel-MytB and its application | |
CN115851491A (en) | Lactobacillus plantarum and its application | |
Duman-Özdamar et al. | High-yield production of active recombinant S. simulans lysostaphin expressed in E. coli in a laboratory bioreactor | |
CN108823193B (en) | A high-efficiency Streptococcus pneumoniae chimeric lyase and its mutants and applications | |
CN114736894B (en) | Chimeric enzyme ClyQ for degrading staphylococcus biofilm and preparation method and application thereof | |
Shin et al. | Characterization of thermostable bacteriophage CPD2 and its endolysin LysCPD2 as biocontrol agents against Clostridium perfringens | |
CN114106197B (en) | Narrow-spectrum antibacterial peptide and application thereof | |
CN114990098B (en) | Preparation method and application of lyase, encoding gene, composition and bacteriostatic agent | |
CN112961847B (en) | Application of Bacillus belgii YtnP-homologous lactonase in oral cavity department hygiene disinfection | |
CN114774391B (en) | Bacteriophage lysin for resisting escherichia coli and application thereof | |
CN115820616A (en) | A kind of phage lyase with fluorescent label and its application | |
CN117844788A (en) | Preparation method and application of marine-derived bacteriophage lytic enzyme | |
Bunyan et al. | Phenotypic detection and biofilm formation among Pseudomonas aeruginosa isolated from different sites of infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
OL01 | Intention to license declared | ||
OL01 | Intention to license declared | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20201103 Assignee: Yunnan Senyao Biotechnology Co.,Ltd. Assignor: Kunming University of Science and Technology Contract record no.: X2024980016894 Denomination of invention: A room temperature lytic enzyme Sly and a nucleotide encoding this enzyme Granted publication date: 20220524 License type: Open License Record date: 20240930 |
|
EE01 | Entry into force of recordation of patent licensing contract |